ライフサイエンスコーパス: v

1 paritaprevir failure include R155K and D168E/V.

2 of 0.92 V, and a half-wave potential of 0.82 V.

3 uts arising from superficial layers to layer V.

4 odes (VEs) and factors associated with major VEs.

5 vey (median score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0 [

6 d an ASCVD event (0.390; 95% CI, 0.312-0.467 vs 0.08; 95% CI -0.001 to 0.181) and to result in more a

7 but statistically significant (0.2 [SD 1.1] vs 0.1 [1.1], p=0.010) difference between the two groups

8 with the placebo group (0.149 mean episodes vs 0.146 mean episodes; p=0.522).

9 The mean (SD) SMR was 0.46 (1.06) vs 0.50 (1.50) events per year in the every 4 weeks vs e

10 ised towns: 1.13, SMR 0.83, 95% CI 0.77-0.88 vs 0.73, 0.69-0.77, respectively) and from 1999 to 2006

11 atients below or above the median risk (0.77 vs 0.75; P = .92).

12 and from 1999 to 2006 (1.15, 0.91, 0.86-0.97 vs 0.79, 0.75-0.84).

13 ed to T2DM subjects (0.037 +/- 0.004 mum(-2) vs. 0.023 +/- 0.003 mum(-2) , P = 0.024) that were non-s

14 and slightly worse postoperative BCVA (0.06 vs. 0.03 logMAR, P = 0.039).

15 in the supplement group [43.85 +/- 18.98 mm vs. 0.05 +/- 9.57 mm shift; effect size: 2.9; F(1,39) =

16 -significantly smaller (0.27 +/- 0.01 mum(2) vs. 0.32 +/- 0.02 mum(2) , P = 0.197, Trained vs. T2DM).

17 eyes had worse mean preoperative BCVA (0.55 vs. 0.36 logarithm of the minimum angle of resolution (l

18 nt than did placebo (decrease of 2.02+/-2.32 vs. 0.56+/-1.39 ng per milliliter, P=0.02).

19 ity (intraclass correlation coefficient=0.66 vs. 0.61); convergent validity (r with comprehensive mea

20 inued access registry, both at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7%

21 alue(66% vs. 50%) and area under curve (0.81 vs. 0.70) improved significantly (P < 0.05) with SAFIRE.

22 nsistency reliability (Cronbach's alpha=0.81 vs. 0.88); test-retest reliability (intraclass correlati

23 t group (2-year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.

24 he curve (AUC) was 0.984 for DCEMRI+HB phase vs. 0.934 for DCEMRI (p<0.68) and 0.852 for DCECT (p<0.0

25 r mean BCVA improvement after surgery (-0.50 vs. -0.32 logMAR, P < 0.001), and slightly worse postope

26 ht reduction with tolvaptan (-2.4 +/- 2.1 kg vs. -0.9 +/- 1.8 kg; p < 0.001).

27 epitopes present in the vast majority of Bet v 1 isoforms.

28 lack Caribbean and 2 [1-5] for black African vs 1 [1-2] for white British), and although black Caribb

29 nts had more renal vascular thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).

30 21.7%; P > .99), and 90-day mortality (3.3% vs 1.3%; P = .38).

31 ranging from approximately 0.03 to 1.7 cm(2) V(-1) s(-1) .

32 effect mobilities (41 for holes and 80 cm(2) V(-1) s(-1) for electrons) and device stability are impr

33 trahigh Hall mobility value of >20,000 cm(2) V(-1) s(-1) is measured in as-grown Bi2O2Se nanoflakes a

34 ed the greatest shift in mobility (1.58 cm(2)V(-1)s(-1)) compared the DMMP monomer (1.63 cm(2)V(-1)s(

35 )s(-1)) compared the DMMP monomer (1.63 cm(2)V(-1)s(-1)).

36 in II group than in the placebo group (-1.75 vs. -1.28, P=0.01).

37 on of diabetes (10 years [range, 1-25 years] vs 10 years [range, 2-26 years]), and mean body mass ind

38 Hospital mortality was similar (12.4% vs 10.3%; p = 0.635).

39 ond (median, 3.5 vs 9), and third (median, 0 vs 10.5) assessments (all p < 0.001).

40 men (total, 12.2 vs 17.6; first or last, 6.8 vs 10.7; P < .001 for both comparisons).

41 al stay for the moderate group was 12.4 days vs 10.9 days in the intensive group (absolute difference

42 and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.8

43 less hands-on time (mean +/- SD) (87 +/- 41 vs 109 +/- 33 s; p = 0.037) and a longer delay before th

44 d lower rates of cross-over to resection (5% vs 11%; P< 0.0001) and development of carcinoma (1% vs 3

45 nged air leakage (7.8% in the FOREseal group vs 11.3% in the control group, P = 0.264) and the averag

46 on of taxa at higher vs. lower latitudes (8% vs. 11% of genera), despite 11-fold lower abundance (1.2

47 l was observed between the two groups (102.7 v 115.7 months, respectively).

48 nera), despite 11-fold lower abundance (1.2% vs. 12.7% of basal area).

49 ss more than 300 genes in all patients (7.1% vs. 128%; P < 0.001).

50 individuals with more severe TBI (GCS, </=12 vs 13-15).

51 an clinically diagnosed cases (48/77 (62.3%) vs 13/41 (31.7%), p < 0.001).

52 35) and the composite outcome (1680 [12.2%]) vs 1383 [10.1%]; % absolute RD, 2.16; 95% CI, 1.43-2.89)

53 black Caribbean and 38.9% for black African vs 14.8% for white British), these differences were not

54 s), HER2 positivity remained constant (15.7% v 15.5%, respectively).

55 the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confi

56 o 1.36; 95% CI 1.04-1.78; adjusted rates 20% vs 16%; P = 0.023), more readmissions (odds ratio 1.57;

57 emission with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission

58 st author publications than men (total, 12.2 vs 17.6; first or last, 6.8 vs 10.7; P < .001 for both c

59 ested increased between 2012 and 2014 (2,201 v 2,558 patient cases; 2,278 v 2,659 tumors), HER2 posit

60 and 2014 (2,201 v 2,558 patient cases; 2,278 v 2,659 tumors), HER2 positivity remained constant (15.7

61 (IQR, 1.0-2.0) pulmonary complications score vs 2.1 (95% CI, 2.0-2.3) and 2.0 (IQR, 1.5-3.0) for the

62 taxel (median 4.07 months [95% CI 2.96-4.47] vs 2.76 months [2.60-2.96]; hazard ratio [HR] 0.757, 95%

63 likely to have a longer hospital stay (2.9 d vs. 2.5 d, P <0.001) and were more likely to be discharg

64 ischarged to a rehabilitation facility (3.6% vs. 2.5%, P <0.001), adjusting for covariates.

65 xperienced similar rates of cyst growth (19% vs. 20%; P= 0.95) and lower rates of cross-over to resec

66 cy end point: in trial A, 188 of 254 (74.0%) vs 21 of 254 (8.3%; P < .001), for a difference in propo

67 .5 days; P = .31), 30-day readmission (22.4% vs 21.7%; P > .99), and 90-day mortality (3.3% vs 1.3%;

68 l eyes in both the superficial (17.68 mm(-1) vs. 21.55 mm(-1); P < 0.001) and deep (21.19 mm(-1) vs.

69 27 (46.6%) patients treated with ruxolitinib vs 23 (44.2%) with BAT (P = .40).

70 complications (Accordion grade >/=3, 23.05% vs 23.7%; P > .99), hospital stay (median: 8 vs 8.5 days

71 iders compared with all other providers (38% vs. 23% by volume, P < 0.001; 79% vs. 56% by total cost,

72 rval (CI) 2.8%-15.6%; adjusted means $26,604 vs $24,263; P = 0.005), 12.4% longer length of stay (95%

73 gressive elevations in ICP (supine, 15 +/- 2 vs. 24 h head-down tilt, 15 +/- 4 mmHg).

74 55 mm(-1); P < 0.001) and deep (21.19 mm(-1) vs. 24.38 mm(-1); P < 0.001) networks.

75 increased in the SA CMC group (31.2 +/- 1.0% vs. 24.7 +/- 2.2% in vehicle-treated mice; p < 0.05) but

76 4%-72.1%) and in trial B, 192 of 255 (75.3%) vs 25 of 260 (9.6%; P < .001), for a difference in propo

77 ial, or incomplete hematologic recovery (44% vs. 25%, P<0.001).

78 versus MI not related to a stented site (59% vs. 26%, p = 0.001).

79 601 were classified as having high BPE (71% vs 29%, respectively; P < .001).

80 dex (31.4 kg/m(2) [range, 24.7-48.1 kg/m(2)] vs 29.8 kg/m(2) [range, 22.9-44.0 kg/m(2)]) were not sig

81 ated with less >/= grade 3 pneumonitis (7.9% v 3.5%, P = .039) and a reduced risk in adjusted analyse

82 7; P = .04) but not with heparin plus GPI (0 vs 3 [0.3%]; P = .30).

83 d to a rehabilitation facility after LT (22% vs 3%) and be rehospitalized within the first posttransp

84 P< 0.0001) and development of carcinoma (1% vs 3%; P= 0.008).

85 )-TOC than (64)Cu-DA(IR800)-TOC (5.2 +/- 0.2 vs. 3.6 +/- 0.4 percentage injected dose per gram).

86 rence between PB-type cancers and PDAC (33.3 vs 31.4 months, P = .66).

87 ect a substantially lower response rate (21% vs. 31% and 49%, respectively) and an aging workforce th

88 ted topics during their office visits (70.2% v 32.6%; P < .001).

89 p=0.0034) and less time hyperglycaemic (27% vs 32%; p=0.0279) than did pregnant control participants

90 for which the search process is long ( 1 min vs. 33 min).

91 were observed in patients on nivolumab (14% v 34%).

92 the group that received RVD alone (50 months vs. 36 months; adjusted hazard ratio for disease progres

93 l versus Prograf using observed values (47.7 vs 38.6 mL/min per 1.73 m, P < 0.001) and was superior b

94 21 control) and time spent hypoglycaemic (3% vs 4%; p=0.10).

95 ost 2-fold better fit to the data (R2 = 9.2% vs 4.9%).

96 e control group (31 [33%] of 94 participants vs 42 [49%] of 86 participants, respectively, adjusted o

97 ents who did not receive anticoagulants (71% vs 42%, respectively; P < .0001).

98 de 300 contrast media groups (469 HU +/- 167 vs 447 HU +/- 166, respectively [P = .241]; 95% confiden

99 black Caribbean and 21.9% for black African vs 47.4% for white British) and the number of partners i

100 ent age was 62.1 (20.3) years for ambulatory vs 48.1 (22.3) years for diplopia-related ED visits.

101 isk in the GO arm than in the No-GO arm (26% v 49%; P < .001).

102 stay (95% CI 2.3%-23.5%; adjusted means 5.9 vs 5.2 days; P = 0.015), more complications (odds ratio

103 re similar between groups (6.4 +/- 2.3 mm Hg vs. 5.8 +/- 2.7 mm Hg; p = 0.17), whereas the ViR group

104 r adsorbent recirculating system group (9.5% vs 50.0% with standard medical treatment; p = 0.004), es

105 (82% vs. 62%), positive predictive value(66% vs. 50%) and area under curve (0.81 vs. 0.70) improved s

106 entricular ejection fraction (45.6 +/- 17.4% vs. 55.3 +/- 11.1%; p < 0.001).

107 iders (38% vs. 23% by volume, P < 0.001; 79% vs. 56% by total cost, P < 0.001).

108 ed within the first posttransplant year (78% vs 57%), all P < .001.

109 s (81% vs 61%, P = .20) or at 18 months (67% vs 58%, P = .74).

110 se effect was decreased blood calcium (68.9% vs 59.8%).

111 ce of relapse/nonresponse (CIR/NR; 6% +/- 3% vs 6% +/- 2%; PGray = .03) did not significantly differ

112 o 1.57; 95% CI 1.08-2.29; adjusted rates 10% vs 6%; P = 0.018), and no difference in discharge destin

113 ic group than in the nonhemorrhagic group (1 vs 6.5; P < .001).

114 tral regurgitation moderate or higher (19.4% vs. 6.8%; p = 0.003).

115 DPN, mean age (60 years [range, 38-79 years] vs 61 years [range, 46-75 years], respectively), mean du

116 not significantly different at 6 months (81% vs 61%, P = .20) or at 18 months (67% vs 58%, P = .74).

117 ant CGM users spent more time in target (68% vs 61%; p=0.0034) and less time hyperglycaemic (27% vs 3

118 er stents (</=3 mm; n = 95), specificity(82% vs. 62%), positive predictive value(66% vs. 50%) and are

119 of the occurrence of any complication (73.7% vs 66.4%; P = .21), severe complications (Accordion grad

120 D: 38.5 vs 86.0 months, P = 0.15 [BOS]; 60.5 vs 69.5 months, P = 0.80 [RAS]).

121 SV were listed primary diagnoses in 56 (30%) vs 7 (6%), respectively (P < .0001).

122 longer procedures with bivalirudin (7 [2.1%] vs 7 [0.7%]; relative risk, 2.87; 95% CI, 1.01-8.17; P =

123 te aminotransferase 0 hour, 15.6 +/- 9.3 U/L vs 7 hours, 24.8 +/- 14.6 U/L, P = 0.298).

124 irst 14 days were arm pain (57.4% [27 of 47] vs 7.4% [seven of 94]) and local tenderness (59.6% [28 o

125 the start of chest compressions (109 +/- 77 vs 70 +/- 56 s; p = 0.038).

126 us spp morphotypes and those without (70.48% vs 74.08%; pinteraction=0.86).

127 ted in 70% hypertonic glucose (HG) (group 1) vs 75% HG alone (group 2).

128 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).

129 e without these morphotypes (efficacy 68.62% vs 76.72%; pinteraction=0.652); or between those with La

130 higher risk of 30-day mortality (898 [6.5%] vs 790 [5.8%]; % absolute RD, 0.79; 95% CI, 0.23-1.35) a

131 vs 23.7%; P > .99), hospital stay (median: 8 vs 8.5 days; P = .31), 30-day readmission (22.4% vs 21.7

132 94]) and local tenderness (59.6% [28 of 47] vs 8.5% [eight of 94]).

133 similar among IHO workers and CR adults (12% vs. 8%; aPR: 1.14; 95% CI: 0.56, 2.29).

134 toring group) in France and $11,965 ($93,795 vs. $81,829) in the United States.

135 lung transplantation (low vs high LVD: 38.5 vs 86.0 months, P = 0.15 [BOS]; 60.5 vs 69.5 months, P =

136 87,476 in the gold-standard monitoring group vs. $86,829 in the real-life monitoring group) in France

137 hs or more after diagnosis of breast cancer, vs 87.5% (95% CI, 86.5%-88.4%) for women with no pregnan

138 = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog-rank = .71), and cumulative incidenc

139 irst (median, 0 vs 9.5), second (median, 3.5 vs 9), and third (median, 0 vs 10.5) assessments (all p

140 m than those without at the first (median, 0 vs 9.5), second (median, 3.5 vs 9), and third (median, 0

141 survival was 13.8 months [95% CI 11.8-15.7] vs 9.6 months [8.6-11.2]; hazard ratio [HR] 0.73 [95% CI

142 spectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006).

143 Still, 5-year overall survival (89% +/- 3% vs 90% +/- 4%; Plog-rank = .64), event-free survival (EF

144 icantly reduced (40 deaths [0.025% per year] v 94 deaths [0.038% per year]; HR, 0.65; 95% CI, 0.45 to

145 voltage of 1 V, a threshold voltage of 0.06 V, a subthreshold swing of 83 mV dec(-1) and an on/off r

146 devices exhibited an operating voltage of 1 V, a threshold voltage of 0.06 V, a subthreshold swing o

147 (vs cervical) anastomosis and a thoracotomy (vs absence) have previously been associated with increas

148 sed in CD in the abstinence/saline condition vs acute cocaine and HC.

149 oducible formal potentials of -157 +/- 2 mV (vs Ag/AgCl/3 M KCl) were observed, and the solid-contact

150 the hymen), and delivery method (any vaginal vs all caesarean sections).

151 10 x 10(9) platelets per L) and disease (MDS vs AML).

152 high open-circuit voltage of approximately 1 V and a striking fill factor of approximately 80%.

153 lated mannan oligomers, MOS-III, MOS-IV, MOS-V and MOS-VI consist of tetra-, penta-, hexa-, and hepta

154 sub-pocket at the interface between helices V and VI, which may facilitate the formation of an intra

155 minor (50-1000 copies/mL) viremic episodes (VEs) and factors associated with major VEs.

156 54 eyes, 42 were Reese-Ellsworth group IV to V, and 37 were International Classification of Retinobla

157 ion activity with an onset potential of 0.92 V, and a half-wave potential of 0.82 V.

158 , V, as a novel metric of nodal affiliation: V approximately 0 means that a node is consistently assi

159 ing this approach, we introduce versatility, V, as a novel metric of nodal affiliation: V approximate

160 antiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded).

161 deliveries), prolapse stage (above the hymen vs at or beyond the hymen), and delivery method (any vag

162 are thus needed to functionally characterize V-ATPase and to fully evaluate the therapeutic relevance

163 Existing small-molecule modulators of V-ATPase either are restricted to targeting one membrano

164 fully evaluate the therapeutic relevance of V-ATPase in human diseases.

165 icted to targeting one membranous subunit of V-ATPase or have poorly understood mechanisms of action.

166 ess the proton pumping vacuolar H(+)-ATPase (V-ATPase) and are extensively involved in acid-base home

167 , whereas Sb(III) needs to be oxidized to Sb(V) before being incorporated in the new phase.

168 pients needing full assistance (KPS 10%-40%) vs being independent (KPS 80%-100%) were more likely to

169 nomolar beta1-AR affinity >500-fold beta1-AR vs beta2-AR selectivity and no agonism.

170 ent opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficac

171 Densities of C4d+ and C4d+/annexin V+ (C4d+/AVB+) microvesicles were also increased in AMR

172 The reflectance compensation step in VD calculation significantly improved repeatability, nor

173 nificantly augmented cardiac apoptosis in WT vs. CD-WT mice, which was prevented by co-treatment with

174 more direct topography involving bed nucleus vs central nucleus divisions; (2) CRF content of the CEA

175 Intrathoracic (vs cervical) anastomosis and a thoracotomy (vs absence)

176 we used classical (O395) and El Tor (C6706) V. cholerae biotypes in growth and biochemical assays.

177 ication mechanism that only functions in the V. cholerae El Tor biotype.

178 quires a field strength of approximately 100 V/cm, yet it efficiently recovers proteins and nucleic a

179 Mental status (normal vs. delirium vs. coma) was assessed daily with the Confusion Assessme

180 n 2015 would increase the average national F&V consumption by 7% for 1 y and prevent approximately 18

181 and goal setting mediated the effect of LOW vs CONTROL (50%).

182 accuracy for patients with AD with dementia vs controls (area under the receiver operating character

183 layers to surface; IQR, 8.0-16.9; P = .0098 vs controls).

184 (27.9 +/- 9 nmol x min(-1) x g(-1), P < 0.05 vs. controls) and high-dose subgroups (37.2 +/- 7.8 nmol

185 7.2 +/- 7.8 nmol x min(-1) x g(-1), P < 0.01 vs. controls, P < 0.05 vs. standard-dose).

186 paring data for never vs ever smokers, never vs current smokers, and never vs former smokers.

187 To elucidate such requirements, we used a V(D)J passenger allele system to assay, in mouse GC B ce

188 tween MULE, hAT and Transib elements and the V(D)J recombinase.

189 ntial role in adaptive immunity by mediating V(D)J recombination in developing lymphocytes.

190 Mental status (normal vs. delirium vs. coma) was assessed daily with the Confu

191 dDM pathway, including RNA POLYMERASE V (POL V), DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2) and SA

192 6 months was Roux-en-Y hepaticojejunostomy (vs duct-to-duct) (odds ratio, 3.06; 95% confidence inter

193 mutation status (e.g., EGFR-positive [EGFR+] vs. EGFR-negative) was assessed using the Wilcoxon rank-

194 layers to surface; IQR, 1.5-13.3; P < .0001 vs ERD, BE, and controls) and proximal (median, 5.0 cell

195 D and UC combined), comparing data for never vs ever smokers, never vs current smokers, and never vs

196 (1.50) events per year in the every 4 weeks vs every 12 weeks groups (P = .85).

197 tients administered belatacept every 8 weeks vs every 4 weeks.

198 on, which have distinct selectivity (feature vs. eye of origin) and dynamics (relatively slow vs. rel

199 r, naphthodiperylenetetraimide-vinylene (NDP-V), featuring a backbone of altenating naphthodiperylene

200 er among former smokers (for fourth quartile vs. first quartile, odds ratio (OR) = 2.70, 95% confiden

201 Finally, we show that V. fischeri, purified EroS, and other bacterial chondroi

202 smokers, never vs current smokers, and never vs former smokers.

203 Sb(V) forms a precipitate, whereas Sb(III) needs to be oxid

204 ter depths, habitat features (i.e., brackish vs. freshwaters), and nucleic acids (DNA vs. RNA), sugge

205 and mean (SD) mBESS score (boys, 1.21 [1.5] vs girls, 0.71 [1.0]; mean difference, 0.50 [95% CI, 0.2

206 ted by the child (severity: boys, 15.1 [9.8] vs girls, 11.8 [9.2]; mean difference, 3.31 [95% CI, 1.6

207 ean (SD) total SAC-C score (boys, 23.9 [3.9] vs girls, 24.9 [3.5]; mean difference, -0.92 [95% CI, -1

208 ed by the parent (severity: boys, 11.1 [7.7] vs girls, 9.4 [8.1]; mean difference, 1.63 [95% CI, 0.21

209 iptin treatment increased the relative GLP-1 vs glucagon production in both non-diabetic and diabetic

210 research interest for the development of III-V/graphene functional hybrid heterostructures.

211 nsistently assigned to a specific community; V >> 0 means it is inconsistently assigned to different

212 sis, age (< 60 years), performance status (0 v >/= 1), size of the largest lesion (smaller), and KIT

213 platelet count (<10 x 10(9) platelets per L vs >/=10 x 10(9) platelets per L) and disease (MDS vs AM

214 in MI risk between patients who started PPIs vs H2RAs for the first 12 months, either in the commerci

215 t of BOS or RAS in lung transplantation (low vs high LVD: 38.5 vs 86.0 months, P = 0.15 [BOS]; 60.5 v

216 We compared steatosis estimates by PDFF vs histology.

217 in tear washes of patients with ocular graft-vs-host disease (oGVHD).

218 ent on the level of maturation (depolarizing vs. hyperpolarizing) of postsynaptic GABAA receptor acti

219 that when group IV (i.e., Ti, Zr, and Hf) or V (i.e., Nb and Ta) transition metals are substituted in

220 n the transactivation functions of AR and AR-Vs important for various physiological and disease proce

221 The respective role of UH vs. individual stochasticity varies greatly among demogr

222 subsequent dose of negative potential (-2.0 V) induces the release.

223 is puts a strong constraint on preindustrial vs. industrial-era LUC emissions and suggests that upper

224 g elevated drug levels versus intravenous (i.v.) injection.

225 of population prevalence of chronic shedding vs. intensity and duration of chronic shedding in indivi

226 ation of benzene from an unstable phosphorus(V) intermediate, yielding (C5 Me5 )2 Th[kappa(2) -(C,C')

227 However, marine tests show that vanadium (V) is preferentially extracted over U and many other cat

228 pe of tri-antennary glycan, generated by GnT-V, is not a substrate for FUT8.

229 ctural with SIFSIX-14-Cu-i, exhibited a type V isotherm and no phase change.

230 Adjusting for farm type (broiler vs. layer), the odds of resistance (although not statist

231 (DEGs) were found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

232 erall population, nor in the colon (FFT: 23% vs LFT: 19%, P = 0.636) or rectal (FFT: 44% vs LFT: 35%,

233 any difference between the groups (FFT: 35% vs LFT: 29%, P = 0.290), neither regarding the overall p

234 vs LFT: 19%, P = 0.636) or rectal (FFT: 44% vs LFT: 35%, P = 0.330) cancer subgroups.

235 re treated with intramedullary nail fixation vs locking plate fixation.

236 HIGH SFM+ vs LOW SFM+ (CONTROL matched the dose of LOW).

237 High vs. low daily FA intake was dichotomized at 800mug (medi

238 slightly smaller fraction of taxa at higher vs. lower latitudes (8% vs. 11% of genera), despite 11-f

239 the temperature dependences of LSSE voltage (V LSSE), magnetocrystalline anisotropy field (H K) and s

240 vels of systolic blood pressure (130-149mmHg vs <130mmHg; open label) and to antiplatelet treatment (

241 of water with higher THMs (>95th percentile vs.<25th percentile) and bladder cancer.

242 found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

243 ally expressed genes (DEGs) were found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

244 ssed genes (DEGs) were found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

245 an, 5.0 cell layers to surface; IQR, 2.5-9.3 vs median 10.4 cell layers to surface; IQR, 8.0-16.9; P

246 However, geochemical controls on V mobility within coke deposits remain poorly constraine

247 vioral shifts in the salience of cocaine now vs money later, we found that ketamine, as compared to t

248 s minimised by centre, parity (three or less vs more than three deliveries), prolapse stage (above th

249 0, 1.09), skin tanning ability (for dark tan vs. no tan, multivariable-adjusted RR = 0.98, 95% CI: 0.

250 ariables, the difference in LOS for Medicaid vs non-Medicaid recipients varied significantly by state

251 with greater LTL attrition (3 herpesviruses vs none, beta = -0.07 and P = .02; 4 infections vs none,

252 none, beta = -0.07 and P = .02; 4 infections vs none, beta = -0.14 and P < .001).

253 aMKII) phosphorylation of RyR2-S2814 residue vs. normoglycaemia.

254 an PFS vs those missing <8 days (10.9 months vs not reached).

255 PM status was significantly worse in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hod

256 propensity score-matched analysis of robotic vs open pancreatoduodenectomy to date, and it demonstrat

257 lease assay, Hoechst 33342 staining, annexin V/PI staining, and JC-1 staining.

258 in the placebo group (P<0.001 for each dose vs. placebo), and everyday-activities scores improved by

259 in the placebo group (P<0.001 for each dose vs. placebo).

260 f the RdDM pathway, including RNA POLYMERASE V (POL V), DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2)

261 < .05), higher levels of apoptosis (Annexin V positivity, P < .005), and less lung allergic inflamma

262 sun exposure (for painful burn with blisters vs. practically no reaction, multivariable-adjusted RR =

263 ory strategy, a greater focus on the future (vs. present), and a stronger focus on self-control.

264 2) reduction by chronoamperometry at -0.35V (vs pseudo-Ag/AgCl) using glucose oxidase immobilized on

265 hearing loss and hair color (for black hair vs. red or blonde hair, multivariable-adjusted relative

266 ally done by interrogation of paired H chain V region (VH) and L chain V region (VL) sequences of ind

267 of paired H chain V region (VH) and L chain V region (VL) sequences of individual and Ag-specific B

268 eye of origin) and dynamics (relatively slow vs. relatively fast).

269 that are differentially regulated in latent vs. replicative states of infection.

270 ally polarizing MoS2 at negative potentials (vs RHE) in acidic media or immersing MoS2 into certain a

271 ish vs. freshwaters), and nucleic acids (DNA vs. RNA), suggesting niche differentiation.

272 central, and eastern China], urbanity [urban vs rural], ethnic origin [Han and non-Han], occupation [

273 ts illustrate that for the top 20 meters the V S models that is well constrained by the data, we obta

274 tality ratio in men aged 20-69 years in fast vs slow privatised towns: 1.13, SMR 0.83, 95% CI 0.77-0.

275 and ventral striatum, such that the normal (vs. slow) genotype individuals showed greater functional

276 macular functional impairment (RS decrease) vs SND-.

277 s with follow-up HSCT (inotuzumab ozogamicin vs standard care) was 1.227 (97.5% CI 0.656-2.292; one-s

278 effectiveness of pelvic physiotherapy (PPT) vs standard medical care (SMC) in children with FC.

279 -1) x g(-1), P < 0.01 vs. controls, P < 0.05 vs. standard-dose).

280 tomachs, but the predominant response of W/W(V) stomachs was contraction.

281 ative proportion of C lost to the atmosphere vs. stored or transported downstream.

282 e mammalian ventricular-subventricular zone (V-SVZ) presents the highest neurogenic potential in the

283 s. 0.32 +/- 0.02 mum(2) , P = 0.197, Trained vs. T2DM).

284 rease in advanced disease and AURKA is an AR-V target gene demonstrating a positive feedback mechanis

285 ifference was seen between the placebo patch vs the 100-mug patch.

286 skin MC responses to FcepsilonRI triggering vs those evoked by MRGPRX2.

287 critical analysis of speeds of sound in ILs vs those in classical molecular solvents is presented to

288 e days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not reached).

289 Applying positive potential (+2.0 V) to these PCPs promotes ethylene capture, and subseque

290 l (intravenous or intramuscular) ondansetron vs traditional therapy to resolve the symptoms of acute

291 , or Fitzpatrick skin phototype (for type IV vs. type I, multivariable-adjusted RR = 0.99, 95% CI: 0.

292 incidence and thickness differed in screened vs unscreened patients.

293 Given the potential dispersion of V. velutina, we conclude that vigilance is required over

294 reduction to CO in tetrahydrofuran at -0.48 V vs NHE, the least negative potential reported for a mo

295 As(V) was determined as the difference between total As and

296 aseous and liquid emissions from landfills, (v) waste being recycled, (vi) waste for energy recovery,

297 Similar model with V-wave change as a dichotomous variable showed that pati

298 otomous variable showed that patients with a V-wave decrease of >/=11 mm Hg were 3.8x more likely to

299 romagnetic topological insulator (Bi, Sb)2-x V x Te3.

300 red in aged hearts during ischemia (P < 0.05 vs. young hearts).